Radioembolisation plus sorafenib vs sorafenib monotherapy
Non‐serious adverse events (hyperbilirubinaemia: most frequent) · people with hepatocellular carcinoma
1 finding from 1 review
- Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes onlyno estimate extracted1 study · 341 participantsVery low